Tristan Manalac

Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.

The recent surprise stumble of the antisense therapy Wainua in a late-stage ATTR-cardiomyopathy study doesn't seem to have shaken AstraZeneca, which

Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.

If the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year's total.

Shareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artificially inflated prices.”

Investors are focused on Incyte's late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.

Sanofi is going to “look very deeply” at its late-stage pipeline as part of a portfolio prioritization initiative, though new CEO Belén Garijo didn't commit to shelving a specific number of assets.

As part of the collaboration, Johnson & Johnson will have an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion.

UniQure is ready to put its Huntington's disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by Replimune and Capricor.

Alnylam's revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there's tailwinds in the competitive landscape,” according to Stifel.